Vir Biotechnology Files 8-K on Officer Changes & Compensation

Ticker: VIR · Form: 8-K · Filed: 2024-02-20T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, compensation, 8-K

TL;DR

**Vir Biotechnology just filed an 8-K about changes in its executive team and their pay, so keep an eye on leadership shifts!**

AI Summary

Vir Biotechnology, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 19, 2024. The filing pertains to Item 5.02, specifically regarding the departure or election of directors or officers and compensatory arrangements for certain officers. The company, based in San Francisco, CA, operates in the biological products industry.

Why It Matters

This filing signals potential shifts in leadership or executive compensation at Vir Biotechnology, which could impact the company's strategic direction and financial health.

Risk Assessment

Risk Level: medium — Changes in executive leadership and compensation can introduce uncertainty regarding future company performance and strategy.

Key Players & Entities

FAQ

What was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 19, 2024.

What is the primary subject matter of this 8-K filing?

The primary subject matter of this 8-K filing is Item 5.02, which covers the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

What is the full name of the registrant company?

The full name of the registrant company is Vir Biotechnology, Inc.

Where are Vir Biotechnology, Inc.'s principal executive offices located?

Vir Biotechnology, Inc.'s principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158.

What is the registrant's Commission File Number?

The registrant's Commission File Number is 001-39083.

From the Filing

0001193125-24-040034.txt : 20240220 0001193125-24-040034.hdr.sgml : 20240220 20240220163311 ACCESSION NUMBER: 0001193125-24-040034 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240219 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24654037 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d793408d8k.htm 8-K 8-K false 0001706431 0001706431 2024-02-19 2024-02-19     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2024     Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-39083   81-2730369 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of principal executive offices, including zip code) (415) 906-4324 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   VIR   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 20, 2024, Vir Biotechnology, Inc. (the “Company”) announced that Executive Vice President and Chief Medical Officer, Phil Pang, M.D., Ph.D. has decided to leave the Company at the end of March 2024 to spend more time with his family. The Company has initiated a search for his successor. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the re

View on Read The Filing